Modified 5' utr
AssigneeNutcracker Therapeutics, Inc.
InventorsSamuel Deutch, Daniel Omar Frimannsson, Ole Haabeth
Life of this patent
Estimating the term…
Abstract
The disclosure herein provides examples of modified 5′ UTRs and methods of increasing translation of target mRNA using a modified 5′ UTR.
Claims34
A modified 5′ UTR comprising SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 22, or SEQ ID NO:
- 23.
A polynucleotide sequence comprising a 5′ UTR of hist1h1c or rpl15, wherein the 5′ UTR comprises one or more point mutations that reduce formation of secondary structures in the 5′ UTR.
A method of increasing translation of target mRNA, the method comprising promoting translation with a modified 5′ UTR comprising SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 22, or SEQ ID NO:
- 23, wherein the modified 5′ UTR is upstream of the target mRNA in a polynucleotide sequence.
A method of increasing translation of target mRNA, the method comprising promoting translation with a modified 5′ UTR of hist1h1c or rpl15, wherein the 5′ UTR comprises one or more point mutations that reduce formation of secondary structures in the 5′ UTR, wherein the modified 5′ UTR is upstream of the target mRNA in a nucleotide sequence.
Dependencies are inferred from the claim text.